A research team identified a pathway linking MINK1 activity to glucose metabolism reprogramming in triple-negative breast cancer, exposing a metabolic vulnerability. The study, led by scientists at the State Key Laboratory of Medical Proteomics in Beijing, describes how tumor cells hijack glucose flow to support rapid growth. By targeting MINK1, the authors report a disruption of glucose metabolism that suppresses triple-negative breast cancer growth in the preclinical work described. The findings add mechanistic specificity to cancer metabolic strategies by pointing to a regulator that may be druggable. For the field, the key near-term question is whether the identified metabolic dependency holds across patient-derived contexts and whether it can be paired with existing systemic therapies to improve durability.